JP2019528272A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528272A5 JP2019528272A5 JP2019508847A JP2019508847A JP2019528272A5 JP 2019528272 A5 JP2019528272 A5 JP 2019528272A5 JP 2019508847 A JP2019508847 A JP 2019508847A JP 2019508847 A JP2019508847 A JP 2019508847A JP 2019528272 A5 JP2019528272 A5 JP 2019528272A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- oral
- oral pharmaceutical
- composition according
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 48
- 229940124624 oral corticosteroid Drugs 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 5
- 150000003431 steroids Chemical class 0.000 claims 4
- 208000019505 Deglutition disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 210000003979 eosinophil Anatomy 0.000 claims 2
- 201000000708 eosinophilic esophagitis Diseases 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 229960002714 fluticasone Drugs 0.000 claims 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 230000000291 postprandial effect Effects 0.000 claims 2
- 239000008247 solid mixture Substances 0.000 claims 2
- 239000003826 tablet Substances 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 229960003728 ciclesonide Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000007938 effervescent tablet Substances 0.000 claims 1
- 238000001839 endoscopy Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 229960000676 flunisolide Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000011475 lollipops Nutrition 0.000 claims 1
- 239000007937 lozenge Substances 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 235000012054 meals Nutrition 0.000 claims 1
- 229960001664 mometasone Drugs 0.000 claims 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 1
- 230000002940 repellent Effects 0.000 claims 1
- 239000005871 repellent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000002002 slurry Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131290A JP7526143B2 (ja) | 2016-08-18 | 2021-08-11 | 好酸球性食道炎を処置する方法 |
| JP2024115475A JP2024164004A (ja) | 2016-08-18 | 2024-07-19 | 好酸球性食道炎を処置する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662376703P | 2016-08-18 | 2016-08-18 | |
| US62/376,703 | 2016-08-18 | ||
| US201762461317P | 2017-02-21 | 2017-02-21 | |
| US62/461,317 | 2017-02-21 | ||
| US201762489292P | 2017-04-24 | 2017-04-24 | |
| US62/489,292 | 2017-04-24 | ||
| PCT/US2017/047474 WO2018035393A1 (en) | 2016-08-18 | 2017-08-18 | Methods of treating eosinophilic esophagitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131290A Division JP7526143B2 (ja) | 2016-08-18 | 2021-08-11 | 好酸球性食道炎を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528272A JP2019528272A (ja) | 2019-10-10 |
| JP2019528272A5 true JP2019528272A5 (enExample) | 2020-09-03 |
| JP6929934B2 JP6929934B2 (ja) | 2021-09-01 |
Family
ID=61197039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019508847A Expired - Fee Related JP6929934B2 (ja) | 2016-08-18 | 2017-08-18 | 好酸球性食道炎を処置する方法 |
| JP2021131290A Active JP7526143B2 (ja) | 2016-08-18 | 2021-08-11 | 好酸球性食道炎を処置する方法 |
| JP2024115475A Pending JP2024164004A (ja) | 2016-08-18 | 2024-07-19 | 好酸球性食道炎を処置する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131290A Active JP7526143B2 (ja) | 2016-08-18 | 2021-08-11 | 好酸球性食道炎を処置する方法 |
| JP2024115475A Pending JP2024164004A (ja) | 2016-08-18 | 2024-07-19 | 好酸球性食道炎を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US10105315B2 (enExample) |
| EP (1) | EP3500264A4 (enExample) |
| JP (3) | JP6929934B2 (enExample) |
| KR (3) | KR20190039769A (enExample) |
| AU (2) | AU2017312660B2 (enExample) |
| CA (1) | CA3034264A1 (enExample) |
| NZ (1) | NZ750754A (enExample) |
| RU (1) | RU2766577C2 (enExample) |
| TW (2) | TWI777515B (enExample) |
| UY (1) | UY37370A (enExample) |
| WO (1) | WO2018035393A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| KR20150043548A (ko) | 2009-10-01 | 2015-04-22 | 앱탈리스 파마테크, 인코포레이티드 | 경구 투여용 코르티코스테로이드 조성물 |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| PT3110848T (pt) | 2014-09-24 | 2024-03-05 | Regeneron Pharma | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| KR102872485B1 (ko) | 2016-09-01 | 2025-10-20 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| EP3755432A4 (en) * | 2018-02-21 | 2021-12-01 | Ellodi Pharmaceuticals, L.P. | METHOD OF TREATMENT OF EOSINOPHILIC ESOPHAGITIS |
| MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| US10562930B1 (en) | 2018-08-31 | 2020-02-18 | Praxis Precision Medicines, Inc. | Salts and crystal forms of GABAA positive allosteric modulator |
| US11672959B2 (en) * | 2019-01-18 | 2023-06-13 | Intersect Ent, Inc. | Expandable member systems and methods for drug delivery |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| CA3138386A1 (en) | 2019-05-02 | 2020-11-05 | Intersect ENT International GmbH | Balloon dilation device |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| JP7736667B2 (ja) | 2019-08-05 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 |
| US11188680B2 (en) | 2019-09-20 | 2021-11-30 | International Business Machines Corporation | Creating research study corpus |
| US11321488B2 (en) | 2019-09-20 | 2022-05-03 | International Business Machines Corporation | Policy driven data movement |
| US11328089B2 (en) | 2019-09-20 | 2022-05-10 | International Business Machines Corporation | Built-in legal framework file management |
| US11443056B2 (en) | 2019-09-20 | 2022-09-13 | International Business Machines Corporation | File access restrictions enforcement |
| US11106813B2 (en) * | 2019-09-20 | 2021-08-31 | International Business Machines Corporation | Credentials for consent based file access |
| US11327665B2 (en) | 2019-09-20 | 2022-05-10 | International Business Machines Corporation | Managing data on volumes |
| US12691128B2 (en) | 2019-10-01 | 2026-07-28 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis and reducing candidiasis |
| KR20220074915A (ko) * | 2019-10-01 | 2022-06-03 | 엘로디 파마슈티컬스, 엘.피. | 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법 |
| US11075010B1 (en) * | 2020-03-19 | 2021-07-27 | Insight RX, Inc. | Pharmacology model optimization based on distributed data acquisition |
| CA3180487A1 (en) | 2020-04-16 | 2021-10-21 | The Medical College Of Wisconsin, Inc. | Aerosolized formulations of hiv protease inhibitors for the treatment of airway reflux |
| US20210330900A1 (en) * | 2020-04-22 | 2021-10-28 | Topical Sinus Therapeutics, Inc. | TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE) |
| JP7862322B2 (ja) * | 2020-05-22 | 2026-05-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｌ－４ｒ阻害剤の投与により好酸球性食道炎を処置する方法 |
| BR112023021510A2 (pt) * | 2021-04-20 | 2024-01-30 | Ellodi Pharmaceuticals L P | Métodos de tratamento de estenoses esofágicas |
| CN117715641A (zh) * | 2021-04-26 | 2024-03-15 | 普拉西斯精密医药公司 | 用神经活性类固醇进行治疗的方法 |
| EP4091615A1 (en) * | 2021-05-20 | 2022-11-23 | Dr. Falk Pharma Gmbh | Orodispersible effervescent tablet comprising budesonide for use in the treatment of eosinophilic esophagitis |
| CA3263472A1 (en) * | 2022-07-28 | 2024-02-01 | The Medical College Of Wisconsin, Inc. | Extended-release oral formulation of fosamprenavir for the treatment of reflux |
| WO2025128792A1 (en) * | 2023-12-13 | 2025-06-19 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis and depleting mast cell |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1170188A (en) | 1967-09-15 | 1969-11-12 | Bayer Ag | N-trityl-imidazoles and salts and uses thereof |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| DE2260384C3 (de) | 1972-12-09 | 1979-11-29 | Hoechst Ag, 6000 Frankfurt | Oral zu applizierendes Corticosteroid-Präparat |
| US4080448A (en) | 1974-11-13 | 1978-03-21 | Mirsky Louis H | Method of treating cellular stress |
| BE887518A (fr) | 1980-02-15 | 1981-08-13 | Glaxo Group Ltd | Cartothioates d'androstanes |
| SE8004580L (sv) | 1980-06-19 | 1981-12-20 | Draco Ab | Farmaceutisk beredning |
| CY1359A (en) | 1981-02-02 | 1987-08-07 | Schering Corp | Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them |
| GB8630913D0 (en) | 1986-12-24 | 1987-02-04 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5446070A (en) | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| ZA892859B (en) | 1988-04-22 | 1989-12-27 | Advanced Polymer Systems Inc | Porous particles in preparations involving immiscible phases |
| GB9002375D0 (en) | 1990-02-02 | 1990-04-04 | Pfizer Ltd | Triazole antifungal agents |
| US5278175A (en) | 1990-02-02 | 1994-01-11 | Pfizer Inc. | Triazole antifungal agents |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| CA2101773A1 (en) | 1991-01-31 | 1992-08-01 | Toyoichi Tanaka | Interpenetrating-polymer network phase-transition gels |
| EP0735884B1 (en) | 1993-12-20 | 2000-04-26 | Minnesota Mining And Manufacturing Company | Flunisolide aerosol formulations |
| SE9501384D0 (sv) | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
| GB9517062D0 (en) | 1995-08-18 | 1995-10-25 | Scherer Ltd R P | Pharmaceutical compositions |
| US5863910A (en) * | 1996-01-12 | 1999-01-26 | Bolonick; Joel | Treatment of chronic inflammatory disorders of the gastrointestinal tract |
| DE19606151C2 (de) | 1996-02-20 | 1999-05-12 | Losan Pharma Gmbh | Ibuprofen-Brausezubereitung sowie Verfahren zur Herstellung derselben |
| PT914818E (pt) | 1996-06-14 | 2005-08-31 | Kyowa Hakko Kogyo Kk | Comprimido de desintegracao rapida por via intraoral |
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| SE9604486D0 (sv) | 1996-12-05 | 1996-12-05 | Astra Ab | Novel formulation |
| GB9707934D0 (en) | 1997-04-18 | 1997-06-04 | Danbiosyst Uk | Improved delivery of drugs to mucosal surfaces |
| RO118174B1 (ro) | 1997-08-21 | 2003-03-28 | Aventis Pharma Deutschland Gmbh | Lac de unghii şi utilizarea acestuia |
| EP1058538B9 (en) | 1998-03-06 | 2013-01-02 | Aptalis Pharma S.r.l. | Fast disintegrating tablets |
| FR2781156B1 (fr) | 1998-07-20 | 2001-06-29 | Lafon Labor | Composition pharmaceutique destinee notamment a la prevention et au traitement des radiomucites et des chimiomucites |
| US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
| CN1173703C (zh) | 1999-04-23 | 2004-11-03 | 里奥药物制品有限公司 | 药物组合物 |
| IT1317904B1 (it) | 1999-09-11 | 2003-07-15 | Glaxo Group Ltd | Formulazione farmaceutica di propionato di fluticasone. |
| KR100446101B1 (ko) | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US20030050312A1 (en) | 2001-03-12 | 2003-03-13 | Hjorth Thyge Borup | Novel tablets and capsules and a process for its preparation |
| EP1418945A2 (en) | 2001-03-13 | 2004-05-19 | Angiotech Pharmaceuticals, Inc. | Micellar drug delivery vehicles and uses thereof |
| KR100642976B1 (ko) | 2001-05-10 | 2006-11-10 | 아스텔라스세이야쿠 가부시키가이샤 | 구강내 신속 붕괴성 정제 및 이의 제조방법 |
| US6872405B2 (en) | 2001-05-10 | 2005-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Quick-disintegrating tablet in buccal cavity and manufacturing method thereof |
| US6656493B2 (en) | 2001-07-30 | 2003-12-02 | Wm. Wrigley Jr. Company | Edible film formulations containing maltodextrin |
| FR2831820B1 (fr) | 2001-11-05 | 2004-08-20 | Ethypharm Sa | Comprime orodispersible presentant une grande homogeneite et son procede de preparation |
| US20030206978A1 (en) | 2001-11-29 | 2003-11-06 | Bob Sherwood | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose |
| US20040009212A1 (en) | 2002-01-30 | 2004-01-15 | Pharma Power Biotec Co. Ltd. | Mucoadhesive thermoresponsive medicament-carrier composition |
| JP4173670B2 (ja) | 2002-03-08 | 2008-10-29 | 旭化成ファーマ株式会社 | 口腔内崩壊製剤 |
| MXPA04010778A (es) | 2002-05-03 | 2005-03-07 | Janssen Pharmaceutica Nv | Microemulsiones polimericas. |
| AU2003270357A1 (en) | 2002-09-06 | 2004-03-29 | Microbia, Inc. | Inhibitors of fungal invasion |
| AU2003272450A1 (en) | 2002-09-13 | 2004-04-30 | C. Steven Smith | Novel composition and method for treatment of upper respiratory conditions |
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| WO2004064810A1 (ja) | 2003-01-21 | 2004-08-05 | Nippon Shinyaku Co., Ltd. | 口腔内速崩性錠剤 |
| SI1587514T1 (sl) | 2003-01-31 | 2006-10-31 | Orexo Ab | Hitro ucinkujoc farmacevtski sestavek |
| US20040208833A1 (en) | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
| US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
| US20050009848A1 (en) | 2003-07-10 | 2005-01-13 | Icn Pharmaceuticals Switzerland Ltd. | Use of antivirals against inflammatory bowel diseases |
| US20060134054A1 (en) | 2003-12-19 | 2006-06-22 | Council Of Scientific And Industrial Research | Polymer composition for pH dependent dissolution behavior and process for preparation thereof |
| DE602005014227D1 (de) | 2004-03-10 | 2009-06-10 | Bayer Schering Pharma Ag | Zusammensetzungen aus drospirenon in molekularer dispersion |
| US8545881B2 (en) | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| ATE353635T1 (de) | 2004-09-09 | 2007-03-15 | Medinfar Produtos Farmaceutico | Schnell wasserdispergierbare und domperidon enthaltende tabletten |
| US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
| US20060292099A1 (en) | 2005-05-25 | 2006-12-28 | Michael Milburn | Treatment of eye disorders with sirtuin modulators |
| TW200800142A (en) | 2005-09-09 | 2008-01-01 | Univ Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8497258B2 (en) * | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| JP2007158225A (ja) | 2005-12-08 | 2007-06-21 | Canon Inc | 露光装置 |
| CN1985799B (zh) | 2005-12-19 | 2011-11-09 | 量子高科（北京）研究院有限公司 | 口腔崩解制剂的制备方法 |
| WO2007074472A2 (en) | 2005-12-27 | 2007-07-05 | Jubilant Organosys Limited | Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxide |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| EP1958613A1 (en) | 2007-02-15 | 2008-08-20 | Polichem S.A. | Dermal film-forming liquid formulations for drug release to skin |
| CA2721133C (en) | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| US20090123551A1 (en) | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
| DK3354276T3 (da) * | 2007-11-13 | 2020-03-30 | Meritage Pharma Inc | Sammensætninger til behandlingen af gastrointestinal inflammation |
| US20150231156A1 (en) * | 2007-11-13 | 2015-08-20 | Meritage Pharma, Inc. | Corticosteroid compositions |
| US20090143343A1 (en) * | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| BRPI0820997A2 (pt) | 2007-12-10 | 2014-12-23 | Eurand Inc | Comprimidos de desintegração oral compreendendo difenidramina. |
| BRPI0821761A2 (pt) | 2007-12-21 | 2015-06-16 | Eurand Inc | Composições de comprimidos de desintegração oral de temazepam |
| JP2009173552A (ja) | 2008-01-21 | 2009-08-06 | Lion Corp | 胃腸薬 |
| US20090264392A1 (en) | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
| SI2151235T1 (sl) | 2008-07-21 | 2011-04-29 | Falk Pharma Gmbh | Farmacevtska formulacija za zdravljenje zgornjega prebavnega trakta |
| EP2328558A2 (en) | 2008-08-08 | 2011-06-08 | McNeil-PPC, Inc. | Use of sucralose as a granulating agent |
| EP2328553B1 (en) | 2008-08-20 | 2020-06-10 | The Regents of The University of California | Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| MX2011007578A (es) | 2009-01-15 | 2011-08-04 | Nestec Sa | Metodos para diagnosticar y tratar la disfagia. |
| JP2012518655A (ja) | 2009-02-23 | 2012-08-16 | アプタリス ファーマテック インコーポレイテッド | プロトンポンプ阻害剤を含む制御放出組成物 |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| CN102596237A (zh) | 2009-09-07 | 2012-07-18 | Dbv技术公司 | 治疗嗜酸细胞性食管炎的方法 |
| KR20150043548A (ko) | 2009-10-01 | 2015-04-22 | 앱탈리스 파마테크, 인코포레이티드 | 경구 투여용 코르티코스테로이드 조성물 |
| MX337603B (es) | 2009-11-30 | 2016-03-10 | Adare Pharmaceuticals Inc | Composiciones y tabletas farmaceuticas con recubrimiento compresible y metodos de fabricacion. |
| US20120164080A1 (en) * | 2010-06-24 | 2012-06-28 | Meritage Pharma, Inc. | Methods of treatment for esophageal inflammation |
| NZ611467A (en) | 2010-12-02 | 2015-06-26 | Aptalis Pharmatech Inc | Rapidly dispersing granules, orally disintegrating tablets and methods |
| AU2012208912B2 (en) | 2011-01-18 | 2016-03-03 | Holland Bloorview Kids Rehabilitation Hospital | Method and device for swallowing impairment detection |
| DK2667777T3 (en) | 2011-01-28 | 2016-10-03 | Nestec Sa | APPARATUS FOR DIAGNOSIS OF SAG dysfunction |
| CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
| US20150209432A1 (en) | 2012-07-26 | 2015-07-30 | Lupin Limited | Pharmaceutical compositions of proton pump inhibitor |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| WO2015034678A2 (en) | 2013-09-06 | 2015-03-12 | Aptalis Pharmatech, Inc. | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |
| LT2886108T (lt) * | 2013-12-23 | 2019-03-25 | Dr. Falk Pharma Gmbh | Optimizuota farmacinė kompozicija, skirta stemplės uždegiminių pakitimų gydymui |
| WO2015142739A1 (en) | 2014-03-17 | 2015-09-24 | Children's Hospital Medical Center | Genetic test for determining susceptibility for eosinophilic esophagitis |
| US10176301B2 (en) | 2014-09-11 | 2019-01-08 | Meritage Pharma, Inc. | Systems, methods, and software for providing a patient-reported outcome measure of dysphagia patients with eosinophilic esophagitis |
| US9980975B2 (en) * | 2015-01-22 | 2018-05-29 | Ems S.A. | Dosage forms containing fluticasone propionate for the treatment of inflammatory conditions of the esophagus |
| US10869592B2 (en) | 2015-02-23 | 2020-12-22 | Uroviu Corp. | Handheld surgical endoscope |
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TWI777515B (zh) | 2016-08-18 | 2022-09-11 | 美商愛戴爾製藥股份有限公司 | 治療嗜伊紅性食道炎之方法 |
| EP3755432A4 (en) | 2018-02-21 | 2021-12-01 | Ellodi Pharmaceuticals, L.P. | METHOD OF TREATMENT OF EOSINOPHILIC ESOPHAGITIS |
| US12691128B2 (en) | 2019-10-01 | 2026-07-28 | Ellodi Pharmaceuticals, L.P. | Methods of treating eosinophilic esophagitis and reducing candidiasis |
| KR20220074915A (ko) | 2019-10-01 | 2022-06-03 | 엘로디 파마슈티컬스, 엘.피. | 호산구성 식도염을 치료하고 칸디다증을 감소시키는 방법 |
| WO2022020464A1 (en) | 2020-07-21 | 2022-01-27 | Ellodi Pharmaceuticals, L.P. | Modified release rapidly disintegrating compositions of proton pump inhibitors |
| BR112023021510A2 (pt) | 2021-04-20 | 2024-01-30 | Ellodi Pharmaceuticals L P | Métodos de tratamento de estenoses esofágicas |
-
2017
- 2017-08-17 TW TW110114767A patent/TWI777515B/zh not_active IP Right Cessation
- 2017-08-17 TW TW106127874A patent/TWI728172B/zh active
- 2017-08-18 KR KR1020197007310A patent/KR20190039769A/ko not_active Ceased
- 2017-08-18 RU RU2019105805A patent/RU2766577C2/ru active
- 2017-08-18 KR KR1020237040942A patent/KR20230167146A/ko not_active Ceased
- 2017-08-18 CA CA3034264A patent/CA3034264A1/en active Pending
- 2017-08-18 AU AU2017312660A patent/AU2017312660B2/en active Active
- 2017-08-18 US US15/680,301 patent/US10105315B2/en active Active
- 2017-08-18 WO PCT/US2017/047474 patent/WO2018035393A1/en not_active Ceased
- 2017-08-18 EP EP17842162.4A patent/EP3500264A4/en not_active Withdrawn
- 2017-08-18 JP JP2019508847A patent/JP6929934B2/ja not_active Expired - Fee Related
- 2017-08-18 NZ NZ750754A patent/NZ750754A/en not_active IP Right Cessation
- 2017-08-18 UY UY0001037370A patent/UY37370A/es not_active Application Discontinuation
- 2017-08-18 KR KR1020217023832A patent/KR20210095973A/ko not_active Ceased
-
2018
- 2018-09-14 US US16/131,812 patent/US11026887B2/en active Active
-
2020
- 2020-08-13 US US16/992,671 patent/US20200368147A1/en not_active Abandoned
-
2021
- 2021-05-03 US US17/306,458 patent/US11684571B2/en active Active
- 2021-07-15 US US17/376,996 patent/US11896710B2/en active Active
- 2021-08-11 JP JP2021131290A patent/JP7526143B2/ja active Active
-
2023
- 2023-09-11 US US18/244,500 patent/US12059494B2/en active Active
- 2023-09-20 AU AU2023233115A patent/AU2023233115A1/en active Pending
-
2024
- 2024-06-26 US US18/755,113 patent/US20250170057A1/en active Pending
- 2024-07-19 JP JP2024115475A patent/JP2024164004A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12059494B2 (en) | Methods of treating eosinophilic esophagitis | |
| US12310976B2 (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis | |
| EP4054589A1 (en) | Methods of treating eosinophilic esophagitis and reducing candidiasis | |
| CN107106497A (zh) | 含alpelisib的药物组合物 | |
| TW202308650A (zh) | 治療食道狹窄之方法 | |
| US20220347189A1 (en) | Methods of treating eosinophilic esophagitis and reducing candidiasis | |
| CN119300823A (zh) | 布罗替德用于治疗特发性肺纤维化的用途 | |
| ES2548090T3 (es) | Uso de una suspensión oral que comprende acetato de megestrol para el tratamiento de asma bronquial | |
| CN105209043A (zh) | 噻唑并嘧啶酮用于治疗炎症性肠病的应用 | |
| WO2009056256A1 (en) | Use of megestrol acetate having improved solubility for the treatment of cancer cachexia | |
| HK1225974B (en) | Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis |